F2G Ltd
Research and experimental development on biotechnology · Macclesfield
ActiveUnited KingdomIncorporated 1998Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
No processed account filings
No processed accounts are available in our records.
Registered details
03578625- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 1998-06-10
- Jurisdiction
- —
- Registered office
- LAB B, GROUND FLOOR BLOCK 50, ALDERLEY PARK, MACCLESFIELD, CHESHIRE, SK10 4TG, UNITED KINGDOM
Classification
1 SIC codes72110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
6 matched grantsIMPALA-NET UK: Integral Membrane Proteins And Lipid Assemblies NETwork UKActiveBBSRC · Research Grant · 2026-01-26 – 2029-01-26 · with 8 other participants£513,286whole project
IMPALA-NET UK: Integral Membrane Proteins And Lipid Assemblies NETwork UKActive
BBSRC · Research Grant · 2026-01-26 – 2029-01-26 · with 8 other participants
£513,286
whole project
Aston UniversityleadAstrazeneca UK LimitedCoding BioDJS Antibodies (Abbvie)Domainex (United Kingdom)F2G LtdMaxion TherapeuticsMolecular Dimensions (Calibre Scientific)Peak Proteins (Sygnature Discovery)
Expression, purification and characterization of membrane proteins which are potential antifungal drug targetsActiveBBSRC · Studentship · 2023-09-30 – 2027-09-29 · with 1 other participant£0whole project
Expression, purification and characterization of membrane proteins which are potential antifungal drug targetsActive
BBSRC · Studentship · 2023-09-30 – 2027-09-29 · with 1 other participant
£0
whole project
Aston UniversityleadF2G Ltd
Developing a new class of anti-fungals to face the threat of multidrug resistant Candida aurisMRC · Studentship · 2021-09-30 – 2025-05-14 · with 1 other participant£0whole project
Developing a new class of anti-fungals to face the threat of multidrug resistant Candida auris
MRC · Studentship · 2021-09-30 – 2025-05-14 · with 1 other participant
£0
whole project
How does a new antimicrobial kill the fungi that invade immunosuppressed patients?BBSRC · Studentship · 2020-09-30 – 2024-09-29 · with 1 other participant£0whole project
How does a new antimicrobial kill the fungi that invade immunosuppressed patients?
BBSRC · Studentship · 2020-09-30 – 2024-09-29 · with 1 other participant
£0
whole project
Development of a broad spectrum antifungal seriesLead
Innovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31
£709,876
awarded
Phase I oral safety assessment of a novel antifungal for systemic fungal infectionsLead
Innovate UK · Collaborative R&D · 2014-10-01 – 2016-10-31
£1,331,296
awarded